A comparative study to assess the effect of retreatment with 2 doses of MabThera on disease activity score in patients with active rheumatoid arthritis who have had an inadequate response or intolerance to antiTNF-alfa therapy (SMART)

Trial Profile

A comparative study to assess the effect of retreatment with 2 doses of MabThera on disease activity score in patients with active rheumatoid arthritis who have had an inadequate response or intolerance to antiTNF-alfa therapy (SMART)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SMART
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 22 Nov 2011 Primary endpoint 'C-reactive-protein' has been met according to 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top